Effect of caloric restriction on cardiovascular‐kidney‐metabolic health in young adults: A secondary analysis of the randomised CALERIE trial

Brian L. Claggett reports personal fees from Alnylam, personal fees from Cardior, personal fees from Cardurion, personal fees from Corvia, personal fees from Cytokinetics, personal fees from CVRx, personal fees from Intellia, personal fees from Rocket, outside the submitted work. Eric Ravussin reports consulting fees from Energesis Pharmaceuticals, Eli Lilly USA, Merck, Amway, Novo Nordisk, Altimmune, AbbVie, Amgen Inc., Orbimed and Boehringer Ingelheim. Caroline M. Apovian has served as an advisory board member for Altimmune, BioAge Labs, Biolinq, CinFina Pharma, Cowen and Company, EPG Comm, Vida, Veru, Wave Life Sciences, Form Health, Fractyl Health, Gelesis, Eli Lilly, L-Nutra, NeuroBo Pharmaceuticals, Xeno, Novo Nordisk, Nutrisystem, Optum Rx, Pain Script, Palatin, The Pursuit By You, Redesign Health and ReShape Lifesciences. John W. Ostrominski reports grant support from the National Institutes of Health (5T32HL007604-39 and L30HL175757). The other authors have no other disclosures to report. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70308. Deidentified CALERIE data files are publicly available at https://calerie.duke.edu/. Data S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.